CTOs on the Move

Attain ABA

www.attainaba.com

 
Attain ABA Therapy provides quality ABA therapy to children with autism. Our experienced BCBAs will create a customized treatment plan tailored to YOUR childs needs. Enroll Today!
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.attainaba.com
  • 1000, Potomac Street Northwest
    Washington, DC USA 20007
  • Phone: 215.769.9222

Executives

Name Title Contact Details

Similar Companies

Resau Medisca Network

Resau Medisca Network Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Action Behavior Centers

Founded in 2017, Action Behavior Centers (ABC) is a leading Applied Behavior Therapy (ABA) provider offering comprehensive services and support to improve the lives of children on the autism spectrum. The provider`s high-quality, center-based care combined with its dedication to helping young children reach their full potential has made ABC one of the fastest growing and highest quality providers in the industry. Headquartered in Austin, Texas, ABC operates 54 clinics in Texas, Arizona and Colorado.

SERVICES Hospital Pharmacy Management and Consulting

SERVICES Hospital Pharmacy Management and Consulting is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.